RxDoctor Payments Data

Crystal Walker, MD

Cardiovascular Disease · Athens, ALNPI 1508074105

Payments from drug & device makers

$2,440in general payments, 2019–2025

Across 109 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$505
  • E.r. Squibb & Sons, L.L.C.$269
  • Astellas Pharma US Inc$261
  • Pfizer$236
  • Preventice Services, LLC$190
  • Boehringer Ingelheim$188
  • plus $791 from 14 others

What the payments were for

  • Food & beverage$2,24292%
  • Education$1988%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,440 in reported general payments places this provider in the 40th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$229,663
Medicare patients
1,399
Services billed
5,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban983$947,260
EntrestoSacubitril/Valsartan389$359,350
XareltoRivaroxaban301$316,141
JardianceEmpagliflozin162$152,467
Repatha SureclickEvolocumab68$51,680
FarxigaDapagliflozin Propanediol41$27,463
Ranolazine ErRanolazine205$27,142
MultaqDronedarone Hcl17$26,940
Metoprolol Succinate1,111$20,348
Atorvastatin Calcium945$12,252
Diltiazem 24hr Er (Cd)Diltiazem Hcl250$9,522
Isosorbide Mononitrate ErIsosorbide Mononitrate455$8,353
Rosuvastatin Calcium500$8,138
JanuviaSitagliptin Phosphate12$6,253
Amiodarone Hcl240$5,717

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$236$947,260983 claims
NovartisEntresto$505$359,350389 claims
Johnson & JohnsonXarelto$51$316,141301 claims
Boehringer IngelheimJardiance$188$152,467162 claims
AstraZenecaFarxiga$128$27,46341 claims
Sanofi-aventis U.S. LLCMultaq$69$26,94017 claims
MerckJanuvia$108$6,25312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Athens

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →